source
- Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic diseaseCaspian Therapeutics, a spin‑out from Kura Oncology, announced it is starting operations with $50 million in financing. The capital, led by BVF Partners and joined by Eli Lilly and Kura leadership,…
- Kura Oncology launches Caspian Therapeutics with $50M funding to develop next-generation diabetes drugKura Oncology has created a new biotech called Caspian Therapeutics and secured $50 million in financing to advance a next-generation diabetes treatment. The spinout will focus on KO-7246, a highl…